The global market for benign breast disease and early breast cancer diagnostics is experiencing rapid growth due to increasing incidences of these conditions worldwide. A key driver of this phenomenon is the aging population, coupled with improved diagnostic capabilities and technologies. The market is segmented into various categories based on ser